[A comparison of efficacy of different modalities of treatment for locally-advanced and metastatic non-small lung cancer].
The paper evaluates the efficacy of different modalities of treatment for locally-advanced and metastatic non-small lung cancer (NSLC) (1,316 pts.). Adjuvant chemotherapy was followed by an elevation of median of survival from 14 to 21.5 months at stage III. Combined treatment appeared more effective than distant one (survival of 21 months vs. 18 at stage IIIA and 35 months vs. 21 at stage IIIB); comparatively fewer cases of complications and radiation-related injuries were reported. The highest rates of survival were characteristic of conservative therapy as a component of chemoradiation (median of survival of 15 months at stages IIIA, IIIB and IV). Survival under 3 months was registered among patients without such therapy. Survival rates for timely adequate conservative therapy at stages IIIB and IV of NSLC were similar or higher than those in surgical cases alone (median of survival of 15 months vs.14 and 12.5, respectively). All procedures of specialized antitumor treatment of locally-advanced and metastatic non-small lung cancer were followed by significant increase in quality of life (+10-50%) while the latter parameter was falling dramatically in those without such therapy (15-30% per month). "Latency of process" calls for further research in methods of treatment because it was chiefly responsible for unsatisfactory results of surgery use for NSLC.
Arsen'ev
A I
AI
Barchuk
A S
AS
Kanaev
S V
SV
Shulepov
A V
AV
Morozova
Iu A
IuA
Barchuk
A A
AA
Tarkov
S A
SA
Vedenin
Ia O
IaO
D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality* / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality* / Q000628:therapy*; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate